



# Nanoparticles for Transmucosal Delivery of CRISPR-based Gene Editing Tools in the Lung

Belal Tafech



Supervisor: Dr. Sarah Hedtrich

July 13<sup>th</sup> 2022




# Background: The airway mucus layer

- A thin layer of fluid covering the lung epithelium
- Traps inhaled particles from penetrating into the epithelium
- Subdues delivery of promising therapeutics for pulmonary diseases
  - Cystic Fibrosis



# A promising therapy for Cystic Fibrosis

- Cystic Fibrosis (CF)
  - Monogenetic disorder
  - CFTR gene
  - Current medication
  - Median age of death is 33yrs in Canada
- CRISPR-Cas9: A revolutionary therapy




**The challenge remains in efficiently delivering genetic cargo across the mucus**

# Airway mucus barrier mechanisms

- **Physical barrier**

- Mucin polymers and other mucus contents form a porous network




Average pore size

- Healthy: 200nm
- CF: < 150nm

# Airway mucus barrier mechanisms

- **Biochemical barrier**

- Glycan chains that terminate in negatively charged residues such as sialic acid (green)




# Overall Research Objectives

## Research goals:

1. Determining nanoparticle (NP) characteristics for efficient transmucosal gene delivery in healthy and disease states of the lung
2. Assessing NPs uptake and gene editing efficacy in primary lung epithelial cells

# Nanoparticle Tracking Analysis (NTA)




- The NTA method relies on capturing videos of live NP movement in mucus
- The videos recorded are further analyzed using computer software to obtain median diffusion coefficients of NPs in mucus


# Assessing NP + gene editing cargo diffusivity in mucus

- Lipid nanoparticles (LNPs) encapsulating CRISPR-Cas9 in the form of either
  - mRNA: LNP-mRNA (~50nm)
  - Ribonucleoprotein (RNP) complex: LNP-RNP (~260nm)
- Compared LNP-mRNA vs LNP-RNP diffusivity in mucus using NTA method

# LNP-mRNA vs LNP-RNP in lung mucus



LNP-mRNA  
In mucus




LNP-RNP  
In mucus

# LNP-mRNA (Blue) vs LNP-RNP (Red)

Name	Median Diffusion Coefficient
LNP-mRNA	0.68 $(\mu\text{m})^2/\text{s}$
LNP-RNP	0.31 $(\mu\text{m})^2/\text{s}$

- LNP-mRNA has a 2.19 fold increase in median diffusion coefficient
- At least partially due to LNP-mRNA (~50nm) smaller size than LNP-RNP (~260nm)




## **Testing LNP transport in Cystic Fibrosis mucus**

# LNP-mRNA vs LNP-RNP in Cystic Fibrosis (CF) mucus



LNP-mRNA







LNP-RNP

- The movement of the LNPs was drastically halted in CF mucus
- Factors other than size must be considered

# Impact of sialic acid on capsid diffusivity in mucus

- Mucin has glycan chains that terminate in negatively charged sialic acid residues (green)
- Enhances the trapping of charged particles
- Removed sialic acid from mucin using neuraminidase (NA) at different levels:





<sup>1</sup>Schuster BS et al. Biomaterials. 2013;34(13):3439-3446

<sup>2</sup>Petrou G & Crouzier T. Biomater. Sci. 2018(6): 2282-2297

# Impact of sialic acid removal on diffusivity

- Capsids with small sizes (~20nm) were added to mucus & NTA was performed



- Increase in NP diffusivity with higher % of SA removed in both healthy and CF mucus conditions


Goal 2. Assessing LNP uptake and gene editing efficacy  
in primary lung epithelial cells

# Assessing the transfection efficiency of LNPs in primary lung epithelial cells


- Lipid nanoparticles (LNPs) loaded with mRNA encoding GFP
- Transfected into normal human bronchial epithelial (NHBE) cells
- Successful transfection results in:
  - GFP-mRNA is translated into a GFP protein
  - A green fluorescence can be detected
  - Imaged using fluorescence microscope

# NHBEs transfected with LNPs + eGFP-mRNA


Hoechst (nuclear stain)



GFP (green)






Merged




LNP A  
1 $\mu$ g/mL

LNP B  
1 $\mu$ g/mL




# Gene editing efficacy in primary lung epithelial cells

- LNPs are loaded with
  - CRISPR-Cas9 mRNA or protein
  - SgRNA against HPRT
- Transfected in the primary lung cells
  - Normal human bronchial epithelial (NHBEs) cells
- Real-time PCR: Quantify relative HPRT Indel (insertion or deletion) percentages




# Treating NHBE cells with LNPs + CRISPR-Cas9 mRNA or RNP



- Around 5% gene editing only
- Cas9 RNP appears slightly more potent than Cas9 mRNA

# Treating NHBE cells with CRISPR-Cas9 mRNA or RNP



- Increasing sgRNA to Cas9-protein ratio to 5:1
- Around 10% gene editing
- As sgRNA is degraded faster than Cas9 protein
  - More sgRNA helps overcome this

# Conclusions

- LNP-mRNA showed the highest diffusion in isolated healthy lung mucus
- Mucus isolated from Cystic Fibrosis patients halts the diffusion of LNPs
- Sialic acid removal improves NP diffusivity in healthy and CF conditions
- On the cellular level, LNPs show high uptake in primary lung epithelial cells
- Increasing ratio of sgRNA to Cas9 protein (5:1) improves gene editing

## Acknowledgement: Thank you!

- Dr. Sarah Hedtrich
  - Partho Adhikary
  - Selina Shanta
  - Fatemeh Mohabatpour
  - Zheng (Maomao) Tan
  - Juliana Bolsoni
  - Leah Mappalakayil
  - Gaëlle Wagner
  - Ronja Ebner
  - Danny Liu
- NanoVation Therapeutics
  - Jayesh Kulkarni
- Dr. Pieter Cullis lab
  - Jerry Leung
- Acuitas Therapeutics
  - Molly Sung
  - Paulo Lin
  - Ying Tam
- Dr. Christian Hackenberger (FMP, Berlin)
- Jack Bell Research Centre
  - Stephanie Smith
- St. Paul's Hospital
  - Ekjot Sangha
  - Jiah Jang



# **Thank you!**

## **Questions**